T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes-Reference-Cited by-同舟云学术

T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes

Published:2020-02-27 Issue:4 Volume:99 Page:829-834
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Ting Shi,Mixue Xie,Lixia Zhu,Xueying Li,Wanzhuo Xie,Xiujin Ye^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-03949-z.pdf

Reference18 articles.

1. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 110(2):727–734

2. Soverini S, De Benedittis C, Papayannidis C et al (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era. Cancer. 120(7):1002–1009

3. Pallera A, Altman JK, Berman E et al. NCCN guidelines insights: chronic myeloid leukemia, Version 1.2017. J Natl Compr Cancer Netw 2016; 14 (12): 1505–1512

4. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo D, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N (2017) NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Natl Compr Cancer Netw 15(9):1091–1102

5. Nicolini FE, Basak GW, Kim D, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry L, Kantarjian HM, Cortes JE (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 123(15):2875–2880

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings;Cancers;2023-12-10

2. Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements;Pathobiology;2023-07-25

3. Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS/MS method: Validation and clinical application;Journal of Pharmaceutical and Biomedical Analysis;2023-06

4. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study;Technology in Cancer Research & Treatment;2023-01

5. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia;Blood Cancer Journal;2022-01-28